Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Mubritinib [TAK-165] [366017-09-6]

Research Use Only
AG-CR1-3755
AdipoGen Life Sciences
CAS Number366017-09-6
Product group Chemicals
Estimated Purity>95%
Molecular Weight468.5
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Mubritinib [TAK-165]
  • Delivery Days Customer
    10
  • CAS Number
    366017-09-6
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Molecular Formula
    C25H23F3N4O2
  • Molecular Weight
    468.5
  • Scientific Description
    Chemical. CAS: 366017-09-6. Formula: C25H23F3N4O2. MW: 468.5. Mubritinib (TAK-165) is a selective inhibitor of the human epidermal growth factor receptor 2 (EGFR2; HER2), inhibiting HER2 phosphorylation with an IC50 value of 6nM. It is 4000-fold selective over EGFR, FGFR, PDGFR, JAK1, Src and Blk (IC50 > 25microM). Mubritinib inhibits the proliferation of breast, bladder, kidney and prostate cancer cells in vitro and in vivo. Mubritinib was shown to inhibit autophagy in a HER2-independent manner in cancer cells. Recently shown to be a mitochondrial electron transport chain complex I (NADH-CoQ reductase) inhibitor. Mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity and consequently oxidative phosphorylation (OXPHOS). This agent could be useful for immunometabolism research. Inhibition of electron transport chain in mitochondria leads to blocking of the transfer of electrons from iron-sulfur centers in complex I to ubiquinone. By inhibiting the mitochondrial respiratory complex I, this agent reduces cardiac-cell beat rate, with prolonged exposure resulting in cell death. Complex I inhibition is directly linked to anti-cancer cell activity. - Mubritinib (TAK-165) is a selective inhibitor of the human epidermal growth factor receptor 2 (EGFR2; HER2), inhibiting HER2 phosphorylation with an IC50 value of 6nM. It is 4000-fold selective over EGFR, FGFR, PDGFR, JAK1, Src and Blk (IC50 > 25microM). Mubritinib inhibits the proliferation of breast, bladder, kidney and prostate cancer cells in vitro and in vivo. Mubritinib was shown to inhibit autophagy in a HER2-independent manner in cancer cells. Recently Mubritinib has been shown to be a mitochondrial electron transport chain complex I (NADH-CoQ reductase) inhibitor. Mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity and consequently oxidative phosphorylation (OXPHOS). This agent could be useful for immunometabolism research. Inhibition of electron transport chain in mitochondria leads to blocking of the transfer of electrons from iron-sulfur centers in complex I to ubiquinone. By inhibiting the mitochondrial respiratory complex I, this agent reduces cardiac-cell beat rate, with prolonged exposure resulting in cell death. Complex I inhibition is directly linked to anti-cancer cell activity.
  • SMILES
    FC(F)(F)C(C=C1)=CC=C1/C=C/C2=NC(COC3=CC=C(CCCCN4N=NC=C4)C=C3)=CO2
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    51202000